Pacira Biosciences, Inc. · NASDAQ:PCRX
Pacira Biosciences — Technical Presentation (June 2026)
13 slides from Pacira Biosciences's technical presentation, Jun 24, 2026
Slide 1: Protective effects of IL-1Ra gene therapy on IVD degeneration: in vitro and in vivo findings in Beagle dogs
TM GERMANY GMBH Protective effects of IL-1Ra gene therapy on IVD degeneration: 22 in vitro and in vivo findings in Beagle dogs S. Amir Kamali Regenerative Orthopedics group 24/06/2026 I have no personal conflicts of interest to declare This research is funded by Pacira Germany GmbH.
Slide 2: Gene therapy for early to moderate IVD degeneration
Gene therapy for early to moderate IVD degeneration Vertebral discs One medicine • Long-term expression • Closed Compartment for local treatment Sun Z, et al. Int J Med Sci. 2020 Roh EJ, et al. Int J Mol Sci. 2021 2
Slide 3: Why high-capacity adenoviral vector (HCAd)?
Why high-capacity adenoviral vector (HCAd)? Delivery of larger genes and regulatory elements Higher transduction efficacy Safety: Non replicating, episomal ~100 nm Ricobaraza A, et al. Int J Mol Sci. 2020 3
Slide 4: Target Gene
Target Gene Local IL-1β inhibition using IL-1 receptor antagonist (IL-1Ra) gene delivery ❑ NF-kB promoter => inflammatory- responsive gene therapy AIM: translational potential of IL-1Ra gene therapy. A) in vitro model B) in vivo dog degenerated IVD model Snuggs, J.W, et al. Gene Ther 2025 4
Slide 5: Biological HCAd-IL-1Ra efficacy using a dog inflammation in vitro model
Biological HCAd-IL-1Ra efficacy using a dog inflammation in vitro model Day -10 Day -3 Day -2 Day 0 Day 7 Day 14 + rhTGFβ (10 ng/ml) +/- cIL1β (1 ng/ml) Primary NPCs Seeding Transduction re-differentiation inflammation Pellet N=5 (p1) NPCs (p2) HCAd-IL1-Ra formation n=3 Collect sample Collect sample
Slide 6: IL-1Ra halts IL-1β-induced GAG/ACAN loss and arrests MMP3 and IL-1β expression
IL-1Ra halts IL-1β-induced GAG/ACAN loss and arrests IL-1β-induced MMP3 and IL-1β expression Ctrl HCAd-IL-1Ra Pellet D7 D14 D14+IL-1β D7 D14 D14+IL-1β ✱✱✱✱ N=5 n=3 ✱✱✱✱ ✱ Saf. O/Fast Green ns ✱ ns 80 200µm GAG/DNA (µg/µg) 60 IHC-ACAN 40 50µm 20 IHC-IL-1β 0 7 ) 7 ) D 14 1β D 14 1β D IL D IL (+ (+ 14
Slide 7: In vivo study design & readouts, n=6 female Beagle dogs
In vivo study design & readouts, n= 6 female Beagle dogs T = - 6 weeks Induction of moderate degeneration in lumbar IVDs T= 3 months T= 6 months (partial nuclectomy) Euthanasia T = 0 months (baseline) 2.5E10VP 40µl/disc Cranial Treatment IVDD injection induction Left Right Caudal Lee NN, JOR Spine.
Slide 8: In vivo study design & readouts, n=6 female Beagle dogs
In vivo study design & readouts, n= 6 female Beagle dogs T = - 6 weeks Induction of moderate degeneration in lumbar IVDs T= 3 months T= 6 months (partial nuclectomy) Euthanasia CT T = 0 months (baseline) 2.5E10VP MRI 40µl/disc Cranial Treatment IVDD injection induction Left Right Caudal
Slide 9: Safety assessment, MRI T2 relaxation and GAG/weight results
✓ Safety Assessment: No histopathological adverse effects or tissue abnormalities were observed. • HCAd-IL-1Ra seems to reduce the attenuation of • However, it does not rescue GAG loss at T2 values on MRI tissue level MRI Degenerate control HCAd-IL-1Ra NP GAG/weight @6mo 150 ** 150 200 1 0.0735 0.55
Slide 10: NP tissue: profiling inflammation at 6 months
NP tissue: profiling inflammation at 6 months ▪ NP tissue: inflammatory mediators did not differ between conditions PGE2 Multiplex ELISA 100 ▪ CCL2 80 ▪ IL-6 ✱ ns pg/mg 60 ▪ IL-8 40 ▪ TNF Biochemical ▪ NGF analysis of tissue 20 ▪ IL-10 extracts 0 ▪ IL-12 ▪ VEGF a e -IL l Ad ctr R iv at -1 eg N D C H
Slide 11: HCAd-IL-1Ra reduced the total histological IVD score
✓HCAd-IL-1Ra reduced the total histological IVD score Native Deg ctrl HCAd-IL-1Ra Deg ctrl HCAd-IL-1Ra 20 ns CT scan ACAN (positivity %) 15 IHC-ACAN 10 5 Total IVD score 0 25µm 0.06 rl A ct 1 R -1 eg IL 2 D AB/PR d- A 3 C Histological score H 4 0.07 20 5 25 6 IHC-TBXT TBXT (positivity %) 20 15 10 10
Slide 12: HCAd-IL-1Ra may represent a promising therapeutic strategy to halt IVD degeneration
HCAd-IL-1Ra may represent a promising therapeutic strategy to halt the progression of IVD degeneration at an early to moderate stage • Anti-inflammatory / anti-catabolic effects • The in vitro model mimics IL-1β–driven inflammatory and catabolic degeneration • The protective effect of IL-1Ra was con
Slide 13: Acknowledgments
Acknowledgments Prof. Marianna Tryfonidou Prof. Bjorn Meij Chantal Voskamp Lisanne Laagland Anouk Eversdijk Michelle Teunissen Saskia Plomp Anna Tellegen Irin Kwananocha TM GERMANY GMBH Dr. Kilian Guse Dr. Stanislav Plutizki Dr. Oliver Ast Dr. Gerhard Sponder
Pacira Biosciences — Technical Presentation (June 2026) on 6ix